A Safety, Tolerability, And Pharmacokinetic Trial With CV... | NCT01004822

ID	Type	Description	Link
CVX-241-101	Other Identifier	Alias Study Number

A Safety, Tolerability, And Pharmacokinetic Trial With CV... | NCT01004822 | Trialant

Arms/Interventions Module

Label	Type	Description	Intervention Names
Active Drug	Experimental	Weekly infusions of CVX-241 at specified doses	Drug: CVX-241

Interventions

Name	Type	Description	Arm Group Labels	Other Names
CVX-241	Drug	0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.	Active Drug

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Maximum Tolerated Dose (MTD)	MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced dose limiting toxicity (DLT). DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).	Stage 1: Baseline up to Day 28 (end of cycle 1)
Recommended Phase 2 Dose (RP2D)	RP2D was the highest dose where 0 of 3 or less than (<2) out of 6 participants experience a DLT. DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).	Stage 1: Baseline up to Day 28 (end of cycle 1)

Secondary Outcomes

Measure	Description	Time Frame
Number of Participants With Dose Limiting Toxicities (DLTs)	DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).	Stage 1: Baseline up to Week 4

Contacts/Locations Module

Name	Affiliation	Role
Pfizer CT.gov Call Center	Pfizer	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Premiere Oncology of Arizona		Scottsdale	Arizona	85258	United States
Premiere Oncology, A Medical Corporation

Label	URL
To obtain contact information for a study center near you, click here.	View source

Arm/Group Information

ID	Title	Description
FG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
FG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
FG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
FG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
FG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
FG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
FG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
FG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Periods

Title

Milestones

Reasons Not Completed

Overall Study

Type	Comment	Milestone Data
STARTED		FG0003 subjects FG0013 subjects FG0024 subjects FG0034 subjects FG0044 subjects FG0054 subjects FG0064 subjects FG0075 subjects
Treated		FG0003 subjects FG0013 subjects FG0023 subjects FG0034 subjects FG004
COMPLETED		FG0000 subjects FG0010 subjects FG0020 subjects FG0030 subjects FG004
NOT COMPLETED		FG0003 subjects FG0013 subjects FG0024 subjects FG0034 subjects FG004

Type	Comment	Reasons
Objective progression or relapse		FG0003 subjects FG0013 subjects FG0020 subjects FG003

Baseline Characteristics Module

Arm/Group Information

ID	Title	Description
BG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
BG001	CVX-241 (PF-05057459) 1 mg/kg

Units	Counts
Participants	BG000

Title	Description	Population Description	Parameter Type	Dispersion Type	Unit of Measure	Calculate Percentage	Denominator Units Selected	Denominators	Classes
Age, Continuous			Mean

Outcome Measures Module

Outcome Measures

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Maximum Tolerated Dose (MTD)

MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced dose limiting toxicity (DLT). DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).

Safety analysis set included all randomized participants who received at least 1 dose of study medication. Due to premature termination of the study MTD could not be assessed.

Posted

Stage 1: Baseline up to Day 28 (end of cycle 1)

ID	Title	Description
OG000	All Participants	All participants who received CVX-241 (PF-05057459) 0.3, 3, 6, 12, 15, 18, 25 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in four-week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Adverse Events Module

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Term	Organ System	Source Vocabulary	Assessment Type	Notes	Statistical Information
Diarrhoea	Gastrointestinal disorders	MedDRA 15	Non-systematic Assessment

Term	Organ System	Source Vocabulary	Assessment Type	Notes	Statistical Information
Anaemia	Blood and lymphatic system disorders	MedDRA 15	Non-systematic Assessment

More Info Module

Certain Agreements

Title	Organization	Phone	Extension	Email
Pfizer ClinicalTrials.gov Call Center	Pfizer, Inc.	1-800-718-1021		ClinicalTrials.gov_Inquiries@pfizer.com

Primary

Recommended Phase 2 Dose (RP2D)

RP2D was the highest dose where 0 of 3 or less than (<2) out of 6 participants experience a DLT. DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).

Safety analysis set included all randomized participants who received at least 1 dose of study medication. Due to premature termination of the study RP2D could not be assessed.

Posted

Stage 1: Baseline up to Day 28 (end of cycle 1)

ID	Title	Description
OG000	All Participants	All participants who received CVX-241 (PF-05057459) 0.3, 3, 6, 12, 15, 18, 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0000

Secondary

Number of Participants With Dose Limiting Toxicities (DLTs)

DLT was defined as any of the following events occurring during the first 28 days of study medication and considered at least possibly-related to study medication: any grade 3 or 4 clinically-relevant non-hematologic toxicity, any clinically-significant grade 2 non-hematologic toxicity that requires 14 days to resolve (to grade 1).

Safety analysis set included all randomized participants who received at least 1 dose of study medication.

Posted

Number

participants

Stage 1: Baseline up to Week 4

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0003 OG0013 OG0023 OG003

Title

Denominators

Categories

Title	Measurements
	OG0000± 0 OG0010± 0 OG0020± 0 OG003

Secondary

Number of Participants With Treatment Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)

Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included SAEs and non-SAEs that occurred during the study.

Safety analysis set included all randomized participants who received at least 1 dose of study medication. Data for Stage 2 is not reported due to early termination of the study.

Posted

Number

participants

Baseline up to 28 days after last dose of study medication (last dose = up to Cycle 39)

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0003 OG0013 OG0023 OG003

Title

Denominators

Categories

TEAE

Title	Measurements
	OG0003 OG0013 OG0023 OG003

Secondary

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUCinf]

AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞)u for unbound drug. It is obtained from AUC (0 - t)u plus AUC (t - ∞)u for unbound drug. Study drug was analysed using serum Angiopoietin-2 (Ang2) and plasma Vascular Endothelial Growth Factor (VEGF).

Safety analysis set included all randomized participants who received at least 1 dose of study medication. Here "n" signifies those participants who were evaluable for this measure at specified time points for each arm, respectively. Data for Stage 2 is not reported due to early termination of the study.

Posted

Geometric Mean

Standard Deviation

nanogram*hours per milliliter (ng*hr/mL)

Pre-dose, 1, 2, 4, 6 hours post dose at Day 1 of cycle 1

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0003 OG0013 OG0023 OG003

Title

Denominators

Categories

VEGF Binding: Cycle1/Day 1 (n=3,3,3,4,4,3,4,5)

Title	Measurements
	OG000343000± 113710 OG0011369000± 285830 OG0023719000± 477910

Secondary

Maximum Observed Plasma Concentration (Cmax)

Study drug was analysed using serum Angiopoietin-2 (Ang2) and plasma Vascular Endothelial Growth Factor (VEGF).

Safety analysis set included all randomized participants who received at least one dose of study medication. Here "n" signifies those participants who were evaluable for this measure at specified time points for each arm, respectively. Data for Stage 2 is not reported due to early termination of the study.

Posted

Geometric Mean

Standard Deviation

nanogram per milliliter (ng/mL)

Pre-dose, 1, 2, 4, 6 hours post dose at Day 1, Day 22 of cycle 1

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0003 OG0013 OG0023 OG003

Title

Denominators

Categories

VEGF Binding: Cycle1/Day 1 (n=3,3,3,4,4,4,4,5)

Title	Measurements
	OG0006666± 1118.6 OG00127160± 5159.8 OG00260740± 3404.4 OG003

Secondary

Minimum Observed Plasma Trough Concentration (Cmin)

Due to premature termination of the study Cmin data were not calculated, only certain pre-specified exposure related non compartmental pharmacokinetics (PK) parameters were calculated.

Posted

Pre-dose, 1, 2, 4, 6 hours post dose at Day 1, Day 22 of cycle 1

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0000 OG0010 OG0020 OG003

Secondary

Systemic Clearance (CL)

CL is a quantitative measure of the rate at which a drug substance is removed from the body. Due to premature termination of the study, only certain exposure-related noncompartmental PK parameters were calculated.

Due to premature termination of the study, CL data were not calculated, only certain pre-specified exposure related non compartmental pharmacokinetics (PK) parameters were calculated.

Posted

Pre-dose, 1, 2, 4, 6 hours post dose at Day 1, Day 22 of cycle 1

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0000 OG0010 OG0020 OG003

Secondary

Plasma Decay Half-Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Study drug was analysed using serum Angiopoietin-2 (Ang2) and plasma Vascular Endothelial Growth Factor (VEGF).

Safety analysis set included all randomized participants who received at least one dose of study medication. Data for Stage 2 is not reported due to early termination of the study.

Posted

Mean

Standard Deviation

hours

Pre-dose, 1, 2, 4, 6 hours post dose at Day 1 of cycle 1

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0003 OG0013 OG0023 OG003

Title

Denominators

Categories

VEGF Binding: Cycle1/Day 1 (n=3,3,3,4,4,3,4,5)

Title	Measurements
	OG00044.87± 5.5411 OG00147.20± 6.8986 OG00250.53± 4.6544 OG003

Secondary

Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentrations

VEGF family consists of five glycoproteins known as VEGF-A, -B, -C, and -D, and placental growth factor (PlGF), which bind to three structurally similar receptor tyrosine kinases VEGFR1, VEGFR2, and VEGFR3. The different ligands have distinctive binding specificities for each of the receptors. In response to ligand binding, the VEGFRs activate distinct downstream signalling pathways. VEGFR2 is expressed in the vasculature and is the key mediator of VEGF-induced angiogenesis.

Posted

Mean

Standard Deviation

picogram/milliliter (pg/mL)

Cycle 1/Day 1, Cycle 1/Day 5, Cycle 1/Day 8, Cycle 1/Day 15, Cycle 1/Day 22, Cycle 2/Day 1

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0003 OG0013 OG0023 OG003

Title

Denominators

Categories

CYCLE1/DAY1 (n=3,3,3,4,4,4,4,5)

Title	Measurements
	OG000208.3± 182.51 OG001731.3± 1119.40 OG002308.7± 238.30 OG003

Secondary

Change From Baseline in Serum Angiopoietin-2 (Ang2) Concentrations

Angiopoietin-2 (Ang2) and a related protein, angiopoietin-1 (Ang1) are ligands of the endothelial cell receptor Tie-2, a receptor tyrosine kinase, and are known to mediate the angiogenesis process together with VEGF and other angiogenic regulators. Ang1 stimulates the phosporylation of Tie-2, recruits pericytes to newly formed blood vessels, and promotes their maturation. Ang2 competes with Ang1 for binding of Tie-2, promotes the dissociation of pericytes, and results in unstable blood vessels. In the presence of VEGF and other angiogenic factors, endothelial cells in these unstable vessels proliferate and migrate to form new blood vessels.

Posted

Mean

Standard Deviation

pg/mL

Cycle 1/Day 1, Cycle 1/Day 5, Cycle 1/Day 8, Cycle 1/Day 15, Cycle 1/Day 22, Cycle 2/Day 1

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0003 OG0013 OG0023 OG003

Title

Denominators

Categories

CYCLE1/DAY1 (n=3,3,3,4,4,4,4,5)

Title	Measurements
	OG0003913.3± 701.59 OG0012793.3± 1570.01 OG0025756.7± 4274.81 OG003

Secondary

Number of Anti Drug Antibody Samples With Positive Anti-CVX-241 Antibodies

Results were summarized for overall study population as per planned analysis.

Safety analysis set included all randomized participants who received at least one dose of study medication. Data for Stage 2 is not reported due to early termination of the study.

Posted

Number

samples

Day 1 pre-dose of each cycle up to last dose of study medication (last dose = up to Cycle 39)

ID	Title	Description
OG000	All Participants	All participants who received CVX-241 (PF-05057459) 0.3, 3, 6, 12, 15, 18, 25 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in four-week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG00030

Title

Denominators

Categories

Title	Measurements
	OG00066

Secondary

Objective Response Rate - Percentage of Participants With Objective Response

Percentage of participants with objective response based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). No new lesions. PR was defined as >=30% decrease under baseline of the sum of diameters of all target lesions. The short aixs was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease was defined as not qualifying for CR, PR, and Progressive Disease.

Safety analysis set included all randomized participants who received at least one dose of study medication. Data for Stage 2 is not reported due to early termination of the study.

Posted

Number

percentage of participants

Every 8 weeks from start of treatment until last dose of study medication (last dose = up to Cycle 39)

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0003 OG0013 OG0023 OG003

Title

Denominators

Categories

Complete Response (CR)

Title	Measurements
	OG0000± 701.59 OG0010± 1570.01 OG0020± 4274.81 OG003

Secondary

Participants WithTumor Response of CA-125 Epithelial Ovarian Cancer (EOC)/ Primary Peritoneal Cancer (PPC)

Participants with epithelial ovarian cancer or primary peritoneal cancer having CA-125 levels greater than 2x the upper limit of normal, 2 weeks prior to starting therapy were evaluated for CA-125 response and response is defined as a 50% decrease in CA-125 from a pre-treatment sample. The response was confirmed and maintained for at least 28 days. CA-125 response was calculated as intervening samples and the 28-day confirmatory sample must be less than or equal to (within assay variability of 10%) the previous sample Progression or recurrence based on serum CA-125 is defined according to the participants baseline levels.

Results are not reported for this measure, as, none of the participants could reach out to Stage 2 due to discontinuations of all the participants in Stage 1.

Posted

Stage 2 every cycle

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0000 OG0010 OG0020 OG003

Secondary

Participants With Reduction in Tumor Vascular Permeability: Blood Flow and Blood Volume as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI)

DCE-MRI is a non-invasive method that provides a functional assessment of microvasculature. The technique can measure changes in vascular permeability, extracellular, and extravascular and vascular volumes. Based on its ability to detect vascular changes, DCE-MRI has recently been evaluated as a biomarker of drug efficacy in clinical trials of angiogenesis inhibitors. Assessment of DCE-MRI started at the 3.0 mg/kg dose cohort.

Results are not reported for this measure, as, none of the participants could reach out to Stage 2 due to discontinuations of all the participants in Stage 1.

Posted

Stage 2 predose up to end of study

ID	Title	Description
OG000	CVX-241 (PF-05057459) 0.3 mg/kg	CVX-241 (PF-05057459) 0.3 mg/kg (milligram per kilogram) intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG001	CVX-241 (PF-05057459) 1 mg/kg	CVX-241 (PF-05057459) 1 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG002	CVX-241 (PF-05057459) 3 mg/kg	CVX-241 (PF-05057459) 3 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG003	CVX-241 (PF-05057459) 6 mg/kg	CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG004	CVX-241 (PF-05057459) 12 mg/kg	CVX-241 (PF-05057459) 12 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG005	CVX-241 (PF-05057459) 15 mg/kg	CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG006	CVX-241 (PF-05057459) 18 mg/kg	CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.
OG007	CVX-241 (PF-05057459) 25 mg/kg	CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons.

Units	Counts
Participants	OG0000 OG0010 OG0020 OG003

Ang2 Binding: Cycle1/Day 1 (n=3,1,1,3,3,1,2,2)

Title

Measurements

OG000582900± 609300
OG001NA± NAData was not reported, since the same was not collected if participants were less than (\<) 3, as planned.
OG002NA± NAData was not reported, since the same was not collected if participants were \<3, as planned.
OG00312850000± 4116800
OG00421720000± 5152000
OG005NA± NAData was not reported, since the same was not collected if participants were \<3 as planned.
OG006NA± NAData was not reported, since the same was not collected if participants were \<3, as planned.
OG007NA± NAData was not reported, since the same was not collected if participants were \<3, as planned.

VEGF Binding: Cycle1/Day 22 (n=3,3,3,3,4,4,4,5)

Title	Measurements
	OG0007526± 1382.5 OG00137210± 12217 OG00264610± 6128.6 OG003225200± 53613 OG004350500± 53370 OG005489800± 197080 OG006304200± 39449 OG007567300± 133310

Ang2 Binding: Cycle1/Day 1 (n=3,3,3,4,4,4,4,5)

Title	Measurements
	OG0008056± 1944.3 OG00135490± 14492 OG00269320± 17218 OG003180800± 34121 OG004313400± 52077 OG005455900± 89920 OG006277800± 26998 OG007459100± 103170

Ang2 Binding: Cycle1/Day 22 (n=3,3,3,3,4,4,4,5)

Title	Measurements
	OG0009454± 2011.0 OG00150840± 14031 OG00281410± 4650.8 OG003256000± 83540 OG004404400± 60272 OG005607500± 139340 OG006406800± 60690 OG007600200± 183030

Ang2 Binding: Cycle1/Day 1 (n=3,1,1,3,3,1,2,2)

Title

Measurements

OG00058.87± 8.4583
OG001NA± NAData was not reported, since the same was not collected if participants were \<3, as planned.
OG002NA± NAData was not reported, since the same was not collected if participants were \<3, as planned.
OG00357.10± 11.898
OG00462.53± 7.5871
OG005NA± NAData was not reported, since the same was not collected if participants were \<3. as planned.
OG006NA± NAData was not reported, since the same was not collected if participants were \<3, as planned.
OG007NA± NAData was not reported, since the same was not collected if participants were \<3, as planned.

CYCLE1/DAY5 (n=3,3,3,4,4,4,4,5)

Title	Measurements
	OG000193.3± 193.00 OG001826.7± 911.89 OG002525.3± 282.46 OG003617.3± 311.94 OG0042410.3± 2133.08 OG005637.5± 91.29 OG0065758.8± 8595.09 OG0073463.8± 5076.53

CYCLE1/DAY8 (n=3,3,3,4,4,4,4,5)

Title	Measurements
	OG000255.0± 289.70 OG001712.3± 752.83 OG002392.3± 227.87 OG003316.8± 228.54 OG0042021.0± 1153.51 OG005456.3± 160.88 OG0064120.5± 6036.92 OG0073124.4± 4529.62

CYCLE1/DAY15 (n=3,3,3,4,4,4,4,5)

Title	Measurements
	OG000212.0± 367.19 OG001564.7± 680.62 OG002416.7± 179.06 OG003432.5± 132.14 OG0042426.5± 1615.67 OG005434.3± 212.43 OG0062416.8± 2247.30 OG0072838.6± 4036.03

CYCLE1/DAY22 (n=3,3,3,3,4,4,4,5)

Title	Measurements
	OG000327.7± 446.32 OG001441.0± 596.73 OG002544.3± 269.10 OG003196.3± 73.38 OG0042601.5± 1405.06 OG005444.8± 231.80 OG0062888.0± 3733.88 OG0072447.2± 3163.16

CYCLE2/DAY1 (n=2,3,3,3,4,4,3,4)

Title	Measurements
	OG000394.0± 557.20 OG001414.7± 516.34 OG002636.3± 298.84 OG003230.0± 199.68 OG0042402.5± 1582.10 OG005553.3± 573.44 OG0061283.0± 697.74 OG0072167.8± 2947.41

CYCLE1/DAY5 (n=3,3,3,4,4,4,4,5)

Title	Measurements
	OG00045266.7± 14202.93 OG001128400± 81005.43 OG002214000± 25632.01 OG003272750± 97250.11 OG004199750± 58025.14 OG005140750± 15261.61 OG0061040250± 1458899.67 OG007319760± 161304.33

CYCLE1/DAY8 (n=3,3,3,4,4,4,4,5)

Title	Measurements
	OG00032833.3± 14908.16 OG00184933.3± 53814.16 OG002195667± 39703.06 OG003228000± 87089.99 OG004174750± 42129.76 OG005122850± 26305.07 OG006788750± 1308363.19 OG007332360± 175180.04

CYCLE1/DAY15 (n=3,3,3,3,4,4,4,5)

Title	Measurements
	OG00032633.3± 16323.70 OG001126900± 90126.63 OG002195333± 54151.02 OG003289333± 60302.02 OG004193500± 50836.34 OG005123725± 74040.32 OG006754750± 1197391.99 OG007208440± 148597.92

CYCLE1/DAY22 (n=3,3,3,3,4,4,4,5)

Title	Measurements
	OG00036866.7± 18504.14 OG001128900± 85837.11 OG002262000± 67638.75 OG003296000± 118000.00 OG004255750± 139588.38 OG005123025± 60535.41 OG006786750± 1112399.32 OG007223200± 150193.87

CYCLE2/DAY1 (n=2,3,3,3,4,4,3,4)

Title	Measurements
	OG00046800.0± 141.42 OG001130100± 90157.25 OG002298000± 145578.16 OG003256333± 107802.29 OG004224750± 69935.09 OG005132125± 75906.05 OG006264000± 124755.76 OG007233575± 169090.48